“Kangstem Biotech strives to develop an innovative new drug
for patients suffering from rare and incurable diseases.”
Beginning with the world’s first stem cell therapy for atopic dermatitis, Kangstem Biotech will continue to fulfill the unmet demands of patients suffering from autoimmune diseases by commercializing its therapeutic products.
We promise to become a global leading company by focusing our resource to strategically enter the global market.
In addition, we will do our best to communicate with shareholders and customers to maximize shareholders’ interests.
We sincerely appreciate your continuous support for Kangstem Biotech.
Kangstem Biotech Co., Ltd. CEO
Tae Wha Lee